Microphysiological System Market Soars: USD 148M in 2024 to USD 1134M by 2031 at 34.3% CAGR | Valuates Reports

News provided by

08 May, 2025, 14:43 GMT

BANGALORE, India, May 8, 2025 /PRNewswire/ -- Microphysiological System Market is Segmented by Type (Human Organ and Tissue Models, Disease Models, Non-Human Species Models), by Application (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes).

The Global Market for Microphysiological Systems was valued at USD 148 Million in the year 2024 and is projected to reach a revised size of USD 1134 Million by 2031, growing at a CAGR of 34.3% during the forecast period.

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-20K15201/Global_Microphysiological_System_Market.

Major Factors Driving the Growth Microphysiological System Market:

The Microphysiological System (MPS) market is gaining momentum as a transformative tool in biomedical research, offering more accurate and human-relevant models compared to traditional animal testing. Its growing adoption is fueled by increasing demand in drug development, toxicity screening, disease modeling, and personalized medicine.

The push for ethical research methods, combined with advancements in biomaterials and organ-on-chip technologies, is expanding MPS applications across pharmaceuticals, biotechnology, cosmetics, and academic sectors. As regulatory agencies and research institutions emphasize non-animal alternatives, the market is benefiting from increased funding, strategic collaborations, and rapid technological innovation, ensuring sustained growth and broader commercial viability.

Unlock Insights: View Full Report Now! https://reports.valuates.com/market-reports/QYRE-Auto-20K15201/global-microphysiological-system.

TRENDS INFLUENCING THE GROWTH OF THE MICROPHYSIOLOGICAL SYSTEM MARKET:

Human organ and tissue models play a transformative role in propelling the Microphysiological System (MPS) material market, as they represent a breakthrough alternative to animal testing. These models replicate the structural and functional complexity of human tissues, necessitating high-performance materials that can mimic the native environment of organs. The push for ethical testing practices and regulatory support for non-animal alternatives are encouraging the adoption of MPS platforms in research and drug development. Materials used must ensure cell viability, bio-compatibility, and reproducibility, spurring innovation in polymers, hydrogels, and bioengineered scaffolds. The rising demand for personalized medicine and disease modeling further increases reliance on advanced MPS materials, supporting sustained market growth.

Disease models are essential to driving the Microphysiological System material market, as they allow for the accurate recreation of pathological conditions within a laboratory setting. These models require advanced materials that support dynamic cellular responses and long-term tissue viability. As chronic diseases, neurological disorders, and rare illnesses gain attention, MPS platforms are increasingly being adopted for studying disease progression and testing targeted therapies. The ability of MPS materials to replicate disease-specific microenvironments is critical for improving predictability in preclinical studies. Furthermore, pharmaceutical companies and academic institutions are investing in disease-specific MPS development, pushing the demand for tailored materials that can support precise biological interactions.

Pharmaceutical and biotechnology companies are central to the rapid expansion of the Microphysiological System market, as they seek more predictive, cost-effective, and ethical solutions for drug discovery and development. MPS technologies offer a platform for high-throughput screening and toxicity assessment, reducing dependency on animal models. These companies require advanced biomaterials that can replicate human tissue behavior for applications ranging from early-stage compound testing to post-market surveillance. With rising R&D expenditure and an increasing pipeline of biologics and precision therapies, demand for functional, scalable, and regulatory-compliant MPS materials is surging. Collaborative efforts between industry players and academic researchers further reinforce the material innovation ecosystem in this sector.

The global shift toward ethical research practices is a major driver for Microphysiological Systems. Regulatory authorities, including the FDA and EMA, are increasingly recognizing alternatives to animal testing for toxicity and efficacy studies. This change is pushing pharmaceutical, cosmetic, and academic research toward MPS platforms that rely on advanced materials to simulate human tissue behavior. The ethical pressure from consumer advocacy groups and stricter animal welfare laws further strengthens this trend. As industries prioritize cruelty-free testing methods, the demand for biocompatible and scalable MPS materials continues to rise, thereby expanding the market's scope and adoption across multiple sectors.

Global pharmaceutical companies are heavily investing in innovative drug development pipelines, and Microphysiological Systems offer a powerful tool for early-stage drug screening. These systems reduce the risk of late-stage clinical failure by improving preclinical predictability. High-quality materials used in MPS construction are essential for consistent experimental outcomes. The demand for disease-specific models and personalized therapy testing is accelerating material innovation. As companies seek efficiency, MPS platforms supported by advanced materials reduce development costs and timeframes. This factor is particularly significant in the biotech sector, where speed-to-market is a critical success metric.

Rapid progress in biomaterials science, particularly in polymer chemistry and hydrogel engineering, is significantly impacting the MPS material market. Customizable materials that can support cell growth, allow nutrient diffusion, and mimic organ-specific stiffness are crucial for realistic model development. New materials like self-assembling peptides, hybrid hydrogels, and smart polymers are offering enhanced control over cellular environments. As the range of bioengineered materials expands, so does the feasibility of producing more complex and physiologically accurate MPS platforms. This synergy between material science and biological systems is driving both adoption and product differentiation in the market.

The growing emphasis on personalized medicine has heightened the need for platforms that replicate patient-specific tissue responses. MPS platforms allow researchers to model individual genetic and phenotypic profiles, aiding in the design of targeted therapies. These applications require materials that are adaptable, safe, and capable of long-term culture without degradation. The expansion of organ-on-chip systems and patient-derived cell lines is intensifying demand for modular, customizable materials. As healthcare shifts from generalized treatment to personalized approaches, the Microphysiological System material market stands to benefit through increased adoption across clinical research institutions and biotechnology firms.

Claim Yours Now! https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-20K15201&lic=single-user.

MICROPHYSIOLOGICAL SYSTEM MARKET SHARE

The Microphysiological System market demonstrates varied regional dynamics, with North America taking the lead due to its robust pharmaceutical industry, extensive R&D funding, and regulatory flexibility encouraging non-animal models.

Europe closely follows, driven by stringent ethical laws and active academic collaboration.

Asia-Pacific is rapidly emerging due to growing biotechnology investments, particularly in China, South Korea, and Japan, where innovation hubs are promoting domestic MPS development.

Key Companies:

Cn Bio
Insphero
Altis Biosystems
AlveoliX
Ananda Devices
AxoSim
Bi/ond
BiomimX
Cherry Biotech
Draper Laboratory
Emulate
Hesperos
Mimetas
Netri
Nortis
Tissuse
React4life
Synvivo
TNO
Beijing Daxiang Biotech
Aracari Bio
ImmuONE
Newcells Biotech
StemPharm
Valo Health (TARA Biosystems)
Obatala Sciences

Purchase Chapters: https://reports.valuates.com/request/chaptercost/QYRE-Auto-20K15201/Global_Microphysiological_System_Market.

SUBSCRIPTION

We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.

DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS!

- Microphysiological System and Organoids Market

- Microfluidic Devices For MPS (Microphysiological Systems) Market was valued at USD 373 Million in the year 2024 and is projected to reach a revised size of USD 511 Million by 2031, growing at a CAGR of 4.7% during the forecast period.

- ARM System on Module (SoM) Market was valued at USD 741 Million in the year 2024 and is projected to reach a revised size of USD 1980 Million by 2031, growing at a CAGR of 15.3% during the forecast period.

- Organs-on-chips (OOC) market was valued at USD 88 Million in 2023 and is anticipated to reach USD 622.5 Million by 2030, witnessing a CAGR of 31.2% during the forecast period 2024-2030.

- Artificial Organs and Bionics Market was valued at USD 10480 Million in the year 2024 and is projected to reach a revised size of USD 17150 Million by 2031, growing at a CAGR of 7.4% during the forecast period.

- Organ Preservation Products and Services Market

- Bioartificial Organ Manufacturing Market

- Organ Transplantation Market

- Human Body 3D Scanner Market

- Human Serum Market

- Millimeter Wave Human Body Scanner Market

GET A FREE QUOTE

Valuates Reports
sales@valuates.com
For U.S. Toll-Free Call 1-(315)-215-3225
WhatsApp: +91-9945648335
Website: https://reports.valuates.com
Blog: https://valuatestrends.blogspot.com/
Pinterest: https://in.pinterest.com/valuatesreports/
Twitter: https://twitter.com/valuatesreports
Facebook: https://www.facebook.com/valuatesreports/
YouTube: https://www.youtube.com/@valuatesreports6753